Wilson Sonsini - ECP

insight detail

Wilson Sonsini Advises AliveCor in Series F Financing

  • 08/16/22
  • Client Highlights
  • Biotech
  • Life Sciences
  • Digital Health

On August 16, 2022, AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, announced its Series F Financing led by GE Healthcare. Also joining the round are NGK-NTK (through a CVC partnership with Pegasus Tech Ventures) and existing investors including Khosla Ventures, Bold Capital Partners, Qualcomm Ventures, and WP Global Partners. Wilson Sonsini Goodrich & Rosati advised AliveCor in the financing.

AliveCor will use this financing to advance its mission of becoming a premier provider of end-to-end cardiological care for patients when they are not in front of their cardiologists by introducing subscription services, KardiaCare and KardiaComplete for patients, payers and employers, and KardiaPro for physicians. These subscription services are supported by the company's personal ECG devices, including KardiaMobile, KardiaMobile 6L, and KardiaMobile Card. This financing will also allow for continued advancements in AliveCor's AI roadmap and pipeline of innovations.

The Wilson Sonsini team that advised AliveCor in the transaction includes:

Mark Baudler
Melissa Rick
Amanda Pollard
TJ Tingjie Li
Conor Cannon
Sean Mihaljevich
Hoy Shih

Technology Transactions
Christopher Paniewski

For more information, please see AliveCor’s press release.

ECP Attorneys:

Copyright © 2023 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our privacy policy.